Short-time therapy for advanced gastric cancer
Author Information
Author(s): Schønnemann K R, Jensen H A, Yilmaz M, Jensen B V, Larsen O, Pfeiffer P
Primary Institution: Odense University Hospital
Hypothesis
Can a combination of oxaliplatin, capecitabine, and epirubicin be an effective first-line therapy for patients with non-resectable gastric cancer?
Conclusion
The study found that the combination therapy is convenient and can be administered in an outpatient setting, but further evaluation in a phase III study is needed.
Supporting Evidence
- The overall response rate was 45%, with a median progression-free survival of 6.8 months.
- Median overall survival was 10.1 months.
- Most patients experienced manageable side effects, with no grade 3 or 4 peripheral neuropathy.
Takeaway
Doctors tested a new treatment for stomach cancer that combines three medicines. It worked pretty well and was easy for patients to get.
Methodology
Patients received a combination of epirubicin, capecitabine, and oxaliplatin every three weeks for a maximum of eight cycles.
Limitations
The study was limited by its small sample size and the need for further evaluation in a larger phase III study.
Participant Demographics
Median age was 59 years, with a range of 31 to 74 years; 83% had metastatic disease.
Statistical Information
Confidence Interval
5.2–7.9 months for PFS; 7.9–11.1 months for OS
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website